Abstract

A NOVEL DRUG TIVOZANIB IS TREATMENT ON ADVANCED RENAL CELL CARCINOMA

Ankita U. Amrutkar*, Priya N. Sole, Payal Y. Kadus, Sudarshan N. Nagarale, Vishal B. Babar and Amit V. Pondkule

.

Abstract

Tivozanib is a novel vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGF TKI) that inhibits phosphorylation of vascular endothelial growth Factor receptor (VEGFR). Tivozanib is a VEGF-TKI with high selectivity for VEGF receptors.[1–3] It has been evaluated in several clinical trials including a Phase I and Phase II and phase III trial demonstrating safety and efficacy for patients with advanced clear cell renal cell carcinoma (RCC). Multikinase inhibitors of the vascular endothelial growth factor receptor tyrosine kinases (VEGF-TKIs) comprise nearly all targeted therapies in renal cell carcinoma, having been prospectively tested through large, multiinstitutional phase III trials. The results from Studies show that Tivozanib is generally well tolerated and safe to use in renal cell carcinoma patient. The aim of this review is to investigate, collect & reform the current knowledge in Suitable form about Tivozanib drug.

Keywords: Tivozanib, Efficacy, Renal cell Carcinoma, vascular endothelial growth factor receptor tyrosine kinase, metastatic.